Acquired Epileptic Aphasia Treatment & Management

  • Author: Eli S Neiman, DO; Chief Editor: Amy Kao, MD   more...
 
Updated: Apr 27, 2011
 

Approach Considerations

The treatment of acquired epileptic aphasia (AEA) is far from standard, and many therapeutic modalities have been tried with variable success. Among these are anticonvulsant drugs, corticosteroids (eg, adrenocorticotropin hormone [ACTH]), ketogenic diet, and surgical intervention with multiple subpial transections (MSTs).

The calcium channel blocker nicardipine has been used in the treatment of acquired epileptic aphasia. In the initial report in 4 patients that suggested the use of nicardipine for acquired epileptic aphasia, nicardipine was given in association with anticonvulsant medications (carbamazepine, valproic acid) and corticosteroids (3 of 4 cases). However, cessation of nicardipine was associated with acute speech deterioration. The dose of nicardipine was 1 mg/kg/d or 60 mg/d for large patients.

A few case reports have demonstrated that intravenous gammaglobulin may be useful in acquired epileptic aphasia, but repeated doses may be necessary.[31]

Next

Anticonvulsant Drugs

Many commonly used anticonvulsant agents effective against partial or generalized seizures have been used in acquired epileptic aphasia (AEA) with variable success. Phenobarbital, carbamazepine, and phenytoin are often ineffective in halting the electroencephalographic (EEG) discharges, and aphasia and may worsen the electrographic activity. In a few cases, the drugs may actually worsen the picture, especially in patients with drop seizures and atypical absences.

Valproic acid, ethosuximide, and benzodiazepines alone or in combination have been partially or transiently effective in some cases. Benzodiazepines, especially clobazam (in Europe) and midazolam, have been most effective when given intravenously (IV). Both the impracticality of this mode of administration and its short-lived effect have limited its use.

Diazepam 0.5 mg/kg given rectally (PR) at bedtime is sometimes effective. This treatment is used in 4- to 6-week courses on and off to avoid tachyphylaxis. The Boston Children's Hospital Epilepsy Group has used continuous diazepam 0.5-0.3 mg/kg given orally (PO) in acquired epileptic aphasia for periods up to 1 year.[32]

Several studies have shown levetiracetam to be beneficial when used as monotherapy in the treatment of electrical status epilepticus of sleep (ESES), continuous spike wave in slow-wave sleep (CSWS), and benign idiopathic focal epilepsies in childhood.[33, 34] In a recent study, Kramer et al found clobazam and levetiracetam to be the most efficacious antiepileptic drugs in the treatment of ESES.[35]

In a case report, felbamate 45 mg/kg/d was successful in treating seizures and aphasia.[36] However, the high frequency of aplastic anemia and liver dysfunction with this drug limits its use.

Among the drugs that the US Food and Drug Administration (FDA) has not approved, sulthiame and clobazam are effective in some patients with acquired epileptic aphasia.

Go to Antiepileptic Drugs for complete information on this topic.

Previous
Next

Corticosteroid and Steroid Agents

In 4 cases Lerman et al described, early corticosteroid or adrenocorticotropin hormone (ACTH) therapy improved symptoms of acquired epileptic aphasia (AEA) and normalized the electroencephalogram (EEG). Prolonged steroid therapy with ACTH 80 IU/d (range 0.2-1 U/kg/d from other sources) has been recommended.

Regarding steroids, prednisone 60 mg/d followed by a 3-month taper is commonly used. Another dosing schedule is 3-5 mg/kg/d of prednisone for 3 months. Pulse intravenous (IV) methylprednisolone therapy has been used to induce remission in acquired epileptic aphasia. A dose of 20-30 mg/kg/d for 3-5 d has been used, intervals followed by prednisone 2 mg/kg, which is then tapered after 1-2 months.

Note that steroid reduction may be associated with recurrence of symptoms; 6 months to several years of treatment may be necessary. Some authors have had the impression that early steroid therapy during the deterioration phase may be associated with increased efficacy and decreased need for prolonged treatment.

Buzatu et al reported that corticosteroids can be safely and effectively used in treating children with continuous spike wave in slow-wave sleep (CSWS) and epilepsy.[37] The investigators administered hydrocortisone (initial dose of 5 mg/kg/d and tapered over 21 mo) to 44 children (25 boys) who had CSWS and evaluated its effects on EEG, behavior, and cognition. Positive response to steroids was found during the first 3 months of treatment in 34 children (77.2%), with normalization of EEG in 21 and relapse in 14. Twenty patients (45.4%) were long-term responders after steroid treatment, with a shorter duration of CSWS and significantly higher intelligent quotient/developmental quotient (IQ/DQ).[37]

Adverse effects and contraindications

Treatment with either corticosteroids or ACTH is associated with many complications, including immunosuppression, weight gain, cushingoid appearance, diabetes, hypertension, steroid myopathy, electrolyte imbalances, mood disorders (depression, mania), aseptic osseous necrosis, pathologic fractures, cataracts, and adrenal failure (during or after taper).

Corticosteroids and ACTH are contraindicated in patients with preexisting immunosuppression, a history of aseptic osseous necrosis, untreated tuberculosis, or hookworm infestation (personal case). Both tuberculosis and hookworm infestation may become widespread with corticosteroid treatment. When in doubt, a purified protein derivative (PPD) test for tuberculosis should be administered before treatment is started. Diabetes, glucose intolerance, hypertension, and obesity are relative contraindications that these drugs may aggravate.

Previous
Next

Multiple Subpial Transections

Multiple subpial transections (MSTs) have been used with variable success in acquired epileptic aphasia (AEA). In this procedure, the cortex is sliced in parallel lines in the midtemporal gyrus and perisylvian area to attenuate the spread of the epileptiform activity without causing cortical dysfunction.

Demarcation of the epileptiform discharge-generation area requires complete investigation by using the methohexital suppression test, an intracarotid amobarbital injection to abolish secondary bilateral synchrony, and electrical and magnetic dipole mapping.

Morrell et al reported mixed results in their experience at Rush-Presbyterian hospital with mixed results in 14 patients with acquired epileptic aphasia who underwent multiple subpial transections.[38] Seven of 14 patients recovered age-appropriate speech and no longer needed speech therapy or special education classes. Another 4 (29%) of 14 had marked improvement of speech and understanding of instructions given verbally but still required speech therapy. Eleven patients had language dysfunction for 2 or more years.[38] Sawhney et al reported improvement in all 3 of their patients with acquired epileptic aphasia who underwent this procedure.[39]

Go to Epilepsy Surgery and Outcome of Epilepsy Surgery for complete information on these topics.

Previous
Next

Ketogenic Diet

Experience with ketogenic diet in patients with acquired epileptic aphasia (AEA) is limited. Bergqvist et al found improvement in language, behavior, and seizures in 3 patients with acquired epileptic aphasia refractory to corticosteroids and immunoglobulin treated with ketogenic diet. Improvement was seen in the 3 patients studied for 26, 24, and 12 months.[40]

Nikanorova et al evaluated the effect of ketogenic diet in 5 patients with continuous spike wave in slow-wave sleep (CSWS) that was refractory to steroids and anticonvulsant agents. One patient had full CSWS disappearance, and a second patient had only partial and intermittent improvement.[41] The effects of ketogenic diet on acquired epileptic aphasia and CSWS requires further investigation.

Previous
Next

Consultations

Neuropsychologic testing is mandatory in all patients with acquired epileptic aphasia (AEA).

All patients with acquired epileptic aphasia should be referred for speech therapy. The speech and language therapist has an essential role in the management of these patients. Learning sign language before the patient's recovery can diminish anxiety and improve socialization in these children. Learning sign language does not appear to delay the recovery of speech in cases of acquired epileptic aphasia.

Patients with acquired epileptic aphasia who do not have a response to anticonvulsant medications and steroids or adrenocorticotropin hormone (ACTH) may be considered for multiple subpial transection (MST) at a qualified epilepsy center.

Psychotherapy and psychiatric consultation may be indicated in selected patients with acquired epileptic aphasia in whom the secondary behavioral problems need pharmacologic intervention.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Eli S Neiman, DO  Assistant Professor of Neurology, Seton Hall University School of Graduate Medical Education, Comprehensive Epilepsy Center, New Jersey Neuroscience Institute-JFK Medical Center, Edison, NJ

Eli S Neiman, DO is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, and American Osteopathic Association

Disclosure: UCB Pharma Honoraria Review panel membership; UCB Pharma Honoraria Speaking and teaching; Cyberonics, Inc Honoraria Speaking and teaching

Coauthor(s)

Michael Seyffert  MD, Assistant Professor or Neurosciences, Seton Hall University School of Graduate Medical Education; Project Advisor, Biomedical Engineering, New Jersey Neuroscience Institute, Neurology and Sleep Medicine, JFK Medical Center

Michael Seyffert is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, and Child Neurology Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert Stanley Rust Jr, MD, MA  Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust Jr, MD, MA is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Headache Society, American Neurological Association, Child Neurology Society, International Child Neurology Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Marcio Sotero de Menezes, MD, to the development and writing of the source article.

References
  1. Patry G, Lyagoubi S, Tassinari CA. Subclinical "electrical status epilepticus" induced by sleep in children. A clinical and electroencephalographic study of six cases. Arch Neurol. Mar 1971;24(3):242-52. [Medline].

  2. Feekery CJ, Parry-Fielder B, Hopkins IJ. Landau-Kleffner syndrome: six patients including discordant monozygotic twins. Pediatr Neurol. Jan-Feb 1993;9(1):49-53. [Medline].

  3. Kotagal P. Secondary epileptogenesis [editorial]. J Clin Neurophysiol. Mar 1997;14(2):89. [Medline].

  4. Solomon GE, Carson D, Pavlakis S, et al. Intracranial EEG monitoring in Landau-Kleffner syndrome associated with left temporal lobe astrocytoma. Epilepsia. May-Jun 1993;34(3):557-60. [Medline].

  5. Otero E, Cordova S, Diaz F, et al. Acquired epileptic aphasia (the Landau-Kleffner syndrome) due to neurocysticercosis. Epilepsia. Sep-Oct 1989;30(5):569-72. [Medline].

  6. Perniola T, Margari L, Buttiglione M, et al. A case of Landau-Kleffner syndrome secondary to inflammatory demyelinating disease. Epilepsia. May-Jun 1993;34(3):551-6. [Medline].

  7. Primavera A, Gianelli MV, Bandini F. Aphasic status epilepticus in multiple sclerosis. Eur Neurol. 1996;36(6):374-7. [Medline].

  8. Kang HC, Kim HD, Lee YM. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr Neurol. Aug 2006;35(2):158-61. [Medline].

  9. Huppke P, Kallenberg K, Gartner J. Perisylvian polymicrogyria in Landau-Kleffner syndrome. Neurology. May 10 2005;64(9):1660. [Medline].

  10. Soprano AM, Garcia EF, Caraballo R, Fejerman N. Acquired epileptic aphasia: neuropsychologic follow-up of 12 patients. Pediatr Neurol. Oct 1994;11(3):230-5. [Medline].

  11. Robinson RO, Baird G, Robinson G, Simonoff E. Landau-Kleffner syndrome: course and correlates with outcome. Dev Med Child Neurol. Apr 2001;43(4):243-7. [Medline].

  12. Morrell F. Electrophysiology of CSWS in Landau-Kleffner syndrome. In: Beaumanoir A, Bureau M, Deona T, Mira L, Tassinari CA, eds. Continuous Spikes and Waves During Slow Sleep Electrical Status Epilepticus During Slow Wave Sleep. London, England: John Libbey; 1995:77-90.

  13. Duran MH, Guimaraes CA, Medeiros LL, Guerreiro MM. Landau-Kleffner syndrome: long-term follow-up. Brain Dev. Jan 2009;31(1):58-63. [Medline].

  14. Beaumanoir A. The Landau-Kleffner syndrome. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 2nd ed. London, England: John Libbey Eurotext Ltd. 1992:181-91, 231-43.

  15. Mantovani JF, Landau WM. Acquired aphasia with convulsive disorder: course and prognosis. Neurology. May 1980;30(5):524-9. [Medline].

  16. Paquier PF, Van Dongen HR, Loonen CB. The Landau-Kleffner syndrome or acquired aphasia with convulsive disorder: long-term follow-up of six children and a review of the recent literature. Arch Neurol. Apr 1992;49(4):354-9. [Medline].

  17. Rossi PG, Parmeggiani A, Posar A, et al. Landau-Kleffner syndrome (LKS): long-term follow-up and links with electrical status epilepticus during sleep (ESES). Brain Dev. Mar 1999;21(2):90-8. [Medline].

  18. Rousselle C, Revol M. Relationship between cognitive function and CSWS. In: Beaumanoir A, Bureau M, Deona T, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 2nd ed. London, England: John Libbey Eurotext Ltd; 1995: 123-33.

  19. Caraballo RH, Astorino F, Cersosimo R, et al. Atypical evolution in childhood epilepsy with occipital paroxysms (Panayiotopoulos type). Epileptic Disord. Sep 2001;3(3):157-62. [Medline].

  20. Ferrie CD, Koutroumanidis M, Rowlinson S, et al. Atypical evolution of Panayiotopoulos syndrome: a case report. Epileptic Disord. Mar 2002;4(1):35-42. [Medline].

  21. Scheffer IE, Jones L, Pozzebon M, et al. Autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation. Ann Neurol. Oct 1995;38(4):633-42. [Medline].

  22. Tuchman RF, Rapin I. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates. Pediatrics. Apr 1997;99(4):560-6. [Medline]. [Full Text].

  23. Rapin I. Acquired aphasia in children [editorial]. J Child Neurol. Jul 1995;10(4):267-70. [Medline].

  24. Rapin I. Autistic regression and disintegrative disorder: how important the role of epilepsy?. Semin Pediatr Neurol. Dec 1995;2(4):278-85. [Medline].

  25. Luat AF, Chugani HT, Asano E. Episodic receptive aphasia in a child with Landau-Kleffner Syndrome: PET correlates. Brain Dev. Oct 2006;28(9):592-6. [Medline].

  26. Nickels K, Wirrell E. Electrical status epilepticus in sleep. Semin Pediatr Neurol. Jun 2008;15(2):50-60. [Medline].

  27. Tassinari CA, Cantalupo G, Rios-Pohl L, Giustina ED, Rubboli G. Encephalopathy with status epilepticus during slow sleep: "the Penelope syndrome". Epilepsia. Aug 2009;50 Suppl 7:4-8. [Medline].

  28. Paetau R, Kajola M, Korkman M, et al. Landau-Kleffner syndrome: epileptic activity in the auditory cortex. Neuroreport. Apr 1991;2(4):201-4. [Medline].

  29. Paetau R. Magnetoencephalography in Landau-Kleffner syndrome. Epilepsia. Aug 2009;50 Suppl 7:51-4. [Medline].

  30. Pascual-Castroviejo I, Lopez Martin V, Martinez Bermejo A, Perez Higueras A. Is cerebral arteritis the cause of the Landau-Kleffner syndrome? Four cases in childhood with angiographic study. Can J Neurol Sci. Feb 1992;19(1):46-52. [Medline].

  31. Arts WF, Aarsen FK, Scheltens-de Boer M, Catsman-Berrevoets CE. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia. Aug 2009;50 Suppl 7:55-8. [Medline].

  32. Riviello JJ. The Boston Children's Hospital experience with ESES and LKS course. Paper presented at: Annual Meeting of the American Epilepsy Society; December 2006; San Diego, California.

  33. Kossoff EH, Boatman D, Freeman JM. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav. Oct 2003;4(5):571-5. [Medline].

  34. von Stülpnagel C, Kluger G, Leiz S, Holthausen H. Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood. Epilepsy Behav. Feb 2010;17(2):193-198. [Medline].

  35. Kramer U, Sagi L, Goldberg-Stern H, Zelnik N, Nissenkorn A, Ben-Zeev B. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). Epilepsia. Jun 2009;50(6):1517-24. [Medline].

  36. Glauser TA, Olberding LS, Titanic MK, Piccirillo DM. Felbamate in the treatment of acquired epileptic aphasia. Epilepsy Res. Jan 1995;20(1):85-9. [Medline].

  37. Buzatu M, Bulteau C, Altuzarra C, Dulac O, Van Bogaert P. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia. Aug 2009;50 Suppl 7:68-72. [Medline].

  38. Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain. Dec 1995;118 ( Pt 6):1529-46. [Medline].

  39. Sawhney IM, Robertson IJ, Polkey CE, et al. Multiple subpial transection: a review of 21 cases. J Neurol Neurosurg Psychiatry. Mar 1995;58(3):344-9. [Medline].

  40. Bergqvist AG, Chee CM, Lutchka LM, Brooks-Kayal AR. Treatment of acquired epileptic aphasia with the ketogenic diet. J Child Neurol. Nov 1999;14(11):696-701. [Medline].

  41. Nikanorova M, Miranda MJ, Atkins M, Sahlholdt L. Ketogenic diet in the treatment of refractory continuous spikes and waves during slow sleep. Epilepsia. May 2009;50(5):1127-31. [Medline].

  42. Marescaux C, Hirsch E, Finck S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia. Nov-Dec 1990;31(6):768-77. [Medline].

  43. Okuyaz C, Aydin K, Gucuyener K, Serdaroglu A. Treatment of electrical status epilepticus during slow-wave sleep with high-dose corticosteroid. Pediatr Neurol. Jan 2005;32(1):64-7. [Medline].

  44. Van Hirtum-Das M, Licht EA, Koh S. Children with ESES: variability in the syndrome. Epilepsy Res. Aug 2006;70 Suppl 1:S248-58. [Medline].

Previous
Next
 
Table 1. Long-Term Follow-up of Acquired Epileptic Aphasia
StudyNumber of PatientsMean Follow-up, yNumber of Patients with Normal or Mild Language Problems
Soprano et al[10] (1994) 1283
Mantovani and Landau[15] (1980) 9226
Paquier[16] (1992) 68.13
Rossi[17] (1999) 119.72
Robinson et al[11] (2001) 185.63
Duran et al[13] (2009) 79.51
Total6318 (28.6%)
Table 2. Epileptiform EEG Findings in Autism, Dysphasia, and Epilepsy
SourceDiagnosisNumber of PatientsNumber of Patients with EEGsPatients with Abnormal EEGs (%)
Tuchman et al (1991)Autism with epilepsy424075
Autism without epilepsy1601398
Dysphasia with epilepsy191958
Dysphasia without epilepsy218669
Tuchman and Rapin[22] (1997) PDD or autism585392*NA
With epilepsyNA6659
Without epilepsyNA6659
Without epilepsy but with history of regressionNA15514
Without epilepsy and without history of regressionNA3646
EEG(s) = electroencephalogram(s); NA = not applicable; PDD = personality developmental disorder.



* Sleep EEGs.



Table 3
DiagnosisDeteriorationEEG Patterns
Autistic epileptiform regressionExpressive language, RL, S, verbal and nonverbal communicationCentrotemporal spikes
Autistic regressionExpressive language, RL, S, verbal and nonverbal communicationNormal
Acquired epileptic aphasiaRL, possibly behavioralLeft or right temporal or parietal spikes, possibly ESES
Acquired expressive epileptic aphasiaExpressive language, oromotor apraxiaCentrotemporal spikes
ESESExpressive language, RL, possibly behavioralESES
Developmental dysphasia (developmental expressive language disease)No; lack of expressive language acquisitionTemporal or parietal spikes
Disintegrative epileptiform disorderExpressive language, RL, S, verbal and nonverbal communication, possibly behavioralESES
EEG = electroencephalographic; ESES = electrical status epilepticus of sleep; RL = receptive language; S = sociability.



* Continuous spike and wave of slow-wave sleep (>85% of slow-wave sleep).



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.